FacebookTwitterRedditEmail

Big Pharma: Gouges, Casualties, and the Congressional Remedy!

The Congress can overturn the abuses of Big Pharma and its “pay or die,” subsidized business model for its drugs.

Big Pharma’s trail of greed, power, and cruelty gets worse every year. Its products and practices take hundreds of thousands of lives in the U.S. from over-prescriptions, lethal combinations of prescriptions, ineffective or contaminated drugs, and dangerous side-effects.

The biggest drug dealers in the U.S. operate legally. Their names are emblazoned in ads and promotions everywhere. Who hasn’t heard of Eli Lilly, Merck, Pfizer, and Novartis? Big Pharma revenues and profits have skyrocketed. In 2017, the U.S. consumers spent $333.4 billion on prescription drugs.

There are no price controls on drugs in the U.S. as there are in most countries in the world. Senator Bernie Sanders just took a bus tour to a Canadian pharmacy where insulin cost patients one tenth of what it costs them in the U.S. Yet, remarkably, drug companies, charted and operating in the U.S., charge Americans the highest prices in the world. This is despite the freebies our business-indentured government lavishes on Big Pharma. The FDA weakly regulates drugs, which are supposed to be both safe and effective, before they can be sold. Who funds this FDA effort? The drug industry itself— required by a law it has learned to love.

The Big Pharma lobby doesn’t always get what it craves. In the nineteen seventies, Dr. Sidney Wolfe, director of Public Citizen’s Health Research Group, produced two paperbacks for a wide television audience (e.g. he appeared on the Phil Donahue Show). They were titled, Pills That Don’t Work and Over-the-Counter Pills that Don’t Work. Because of Dr. Wolfe’s tireless efforts, hundreds of different pills were removed from the market, saving consumers billions of dollars and sparing them the side-effects.

Big Pharma’s greatest strength is its hold over Congress. That is where it gets its huge bundle of subsidies and monopolistic privileges. During the first term of George W. Bush, the drug companies got the Republicans and some spineless Democrats to forbid Medicare from negotiating volume discounts with the drug companies, as the Pentagon and VA have done for years. Big Pharma had over 1,200 lobbyists swarming over Capitol Hill to get these handcuffs on Uncle Sam. Lobbyists combined with campaign cash donated by Pharma industry players sealed the deal.

Your Congressional representatives gave the drug giants much in return: Lucrative tax credits to pay Big Pharma to do what they should do anyway—engage in research and development. Drug companies are profitable recipients of taxpayer-funded government research on developing new drugs – and then given monopolies that enable them to impose sky-high prices, even when the purchaser is the very government that funded the invention of the new drugs in the first place.

The drug industry has also made sure there are no price controls on their drugs—whether gifted to them by NIH or developed by drug companies internally. The absence of price controls accounts for new “blockbuster drugs” going for $100,000, or higher, per patient per year. Many drug prices generally increase faster than inflation.

Greed is infinite for Big Pharma. In addition to tax credits, free drug R&D (compliments of the federal government), and no price restraints, the drug companies have moved much production to China and India. No antibiotics are manufactured in the U.S.—a clear national security risk to which the Pentagon and Trump should pay heed. Two new books, China Rx and Bottle of Poison, document the safety risks of poorly inspected labs in those countries exuding pills into your bodies without your minds being told of “country of origin” on the label.

The great hands-on humanitarian organization Doctors Without Borders, operating in 70 countries often under dangerous armed conflicts, lists “Six Things Big Pharma Doesn’t Want You to Know,” in its recent alert letter.

They are:

*Costs of developing new medicines are exaggerated tenfold or more.

*You’re paying twice for your medicines—first as taxpayers and second as consumers or through your government programs.

*Drug companies are not that good at innovation. About two thirds of new drugs (called “me-too drugs”) are no better, and may be riskier, than the ones already in pharmacies. But they are advertised as special.

*Monopoly patents are extended by clever lawyers to block more affordable generic versions. This maneuver is called “ever greening.”
Pharma bullies low and middle income countries like South Africa, Thailand, Brazil, Colombia, and Malaysia that try to curb its rapaciousness. These drug companies use trade rules and the U.S. government towards their brutal goals.

* In the nineteen nineties, a small group of consumer advocates led by Jamie Love, Bill Haddad, and Robert Weissman persuaded Cipla, an Indian drug firm, and Ministries of Public Health to lower the price of AIDS medicines from $10,000 per patient per year price down to $300 (now under $100). The U.S. drug companies were quite willing to let millions die because they couldn’t pay.

* Big Pharma always says they have to have large profits to pay for R&D and innovation. Really? Why then do they spend far more on stock buybacks (one of the metrics for executive compensation), on marketing and advertising than on R&D? Dr. Wolfe exposed this malarkey years ago.

Yet exposure has not stopped the worsening behavior of Big Pharma. Good books by Katharine Greider (The Big Fix) and Dr. Marcia Angell (The Truth About the Drug Companies) are devastating critiques of Big Pharma’s practices. Despite this, the books reach small audiences and are brushed off by the drug giants. Big Pharma is able to ignore these books because it controls most of Congress—candidates rely heavily on the industry for campaign budgets.

But the American people outnumber the drug companies and only the people can actually vote come election time. Focused voters mean more to politicians than campaign money. The August recess for Congress means your lawmakers are back home having personal meetings. Visit them and make known your demands against the “pay or die” industry. Tell them your own stories.

Or better yet, make them come to your town meetings. Remember: “It’s your Congress, people!”

One galvanizing move by an enlightened billionaire could establish a 20 person advocacy group on drug pricing, focusing on Congress and mobilizing citizens back home. Its effect would be decisive for taming the drug industry’s gouging. Any takers: if so contact Public Citizen at medsaccess@citizen.org.

More articles by:

Ralph Nader is a consumer advocate, lawyer and author of Only the Super-Rich Can Save Us! 

bernie-the-sandernistas-cover-344x550
March 31, 2020
Jonathan Cook
Netanyahu Uses Coronavirus to Lure Rival Gantz into ‘Emergency’ Government
Vijay Prashad, Du Xiaojun – Weiyan Zhu
Growing Xenophobia Against China in the Midst of CoronaShock
Patrick Cockburn
Trump’s Chernobyl Moment: the US May Lose Its Status as World Superpower and Not Recover
Roger Harris
Beyond Chutzpah: US Charges Venezuela With Nacro-Terrorism
M. K. Bhadrakumar
Has America Reached Its Endgame in Afghanistan?
Thomas Klikauer
COVID-19 in Germany: Explaining a Low Death Rate
Dave Lindorff
We’ve Met the Enemy and It’s a Tiny Virus
Binoy Kampmark
Barbaric Decisions: Coronavirus, Refusing Bail and Julian Assange
Nicolas J S Davies
Why is the U.S. so Exceptionally Vulnerable to Covid-19?
James Bovard
The Deep State’s Demolition of Democracy
Michael Doliner
Face Off: the Problem With Social Distancing
John Feffer
The Politics of COVID-19
Mel Gurtov
Trump’s Cure and Our Disease
Howard Lisnoff
The Fault Lines of a Failed Society Begin to Open Up Into Chasms
Nino Pagliccia
Cuba: An Example of Solidarity In a Time of Crisis
Ralph Nader
Out of the Coronavirus Crisis Can Come Efficient Historic Changes for Justice
Thomas Stephens
Apocalyptic and Revolutionary Education in Times of Pandemic
Edward Martin
Erik Olin Wright and the Anti-Capitalist Economy
March 30, 2020
Marshall Auerback
Washington Uses the Pandemic to Create a $2 Trillion Slush Fund for Its Cronies
Ron Jacobs
Going After Maduro
Justin Podur
When Economists Try to Solve Health Crises, the Results Can Often be Disastrous
Thomas Knapp
Decarceration: COVID-19 is Opportunity Knocking
Arshad Khan - Meena Miriam Yust
Dying Planet and a Virus Unleashed
William Astore
How My Dad Predicted the Decline of America
Seth Sandronsky
Reclaiming Vacant Homes in the COVID-19 Pandemic
John G. Russell
Racial Profiling Disorder: the All-American Pandemic
Vijay Prashad, Paola Estrada, Ana Maldonado, and Zoe PC
As the World Tackles the COVID-19 Pandemic, the U.S. Raises the Pressure on Venezuela
Laura Flanders
Covid-19: Our Health Crisis is Born of Bigotry
Cesar Chelala
The New World of Coronavirus
Lawrence Wittner
The World’s Major Military and Economic Powers Find Happiness Elusive
Ted Rall
My Dead French Grandfather Helped Me with COVID-19
Rob Okun
A Citizens’ Call to Invoke the Twenty-fifth Amendment
Ashar Foley
COVID-19 Proves It: We Need Medicare-for-All
Robert Koehler
The Virus is Our Teacher
Wim Laven
Are You Prepared to Needlessly Die for Your Country?
Jill Richardson
Stay Home, Stay Angry
ADRIAN KUZMINSKI
What’s Wrong with Ranked Choice Voting
Mike Garrity
Alliance for the Wild Rockies Sues Trump’s Bureau of Reclamation for Bull Trout Fatalities in Saint Mary-Milk River Irrigation Project on the east Side of Glacier National Park
Weekend Edition
March 27, 2020
Friday - Sunday
Rob Urie
Bailouts for the Rich, the Virus for the Rest of Us
Louis Proyect
Life and Death in the Epicenter
Paul Street
“I Will Not Kill My Mother for Your Stock Portfolio”
Jeffrey St. Clair
Roaming Charges: The Scum Also Rises
Pam Martens - Russ Martens
Stimulus Bill Allows Federal Reserve to Conduct Meetings in Secret; Gives Fed $454 Billion Slush Fund for Wall Street Bailouts
Jefferson Morley
Could the Death of the National Security State be a Silver Lining of COVID-19?
Ruth Hopkins
A Message For America from Brazil’s First Indigenous Congresswoman
FacebookTwitterRedditEmail